The 2022 Inflation Reduction Act allowed Medicare to negotiate the prices for 10 common or costly drugs. Those savings — up to 76% on one drug — are on the way for Medicare beneficiaries.
Proposed changes would hinder small businesses’ ability to access funds to expand, innovate and remain competitive and may discourage investments in crucial infrastructure projects.